跳至主要内容
临床试验/NCT02646332
NCT02646332已完成不适用

Comparing the Efficacy and Impact on Gastrointestinal Microbiota of Reverse Hybrid Therapy and Concomitant Therapy in Helicobacter Pylori Eradication

Kaohsiung Veterans General Hospital.1 个研究点 分布在 1 个国家目标入组 248 人开始时间: 2015年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
248
试验地点
1
主要终点
Number of Participants in Which H. Pylori Was Eradicated

研究概览

简要总结

Reverse hybrid therapy achieves a higher eradication rate than concomitant therapy remains unanswered.

详细描述

A 14-day hybrid therapy invented by our study group appears very promising in H. pylori eradication, achieving excellent eradication rates of 99% and 97% according to per-protocol and intention-to-treat analyses, respectively. Recently, the investigators demonstrated that the eradication rate of reverse hybrid therapy was higher than that of standard triple therapy. However, whether reverse hybrid therapy achieves a higher eradication rate than concomitant therapy remains unanswered.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Consecutive H pylori-infected outpatients, at least 20 years of age, with endoscopically proven peptic ulcer diseases or gastritis

排除标准

  • previous H pylori-eradication therapy
  • ingestion of antibiotics or bismuth within the prior 4 weeks
  • patients with allergic history to the medications used
  • patients with previous gastric surgery
  • the coexistence of serious concomitant illness (for example, decompensated liver cirrhosis, uremia)
  • pregnant women

研究组 & 干预措施

(dexlan+amox+clar+metr)+(dexlan+amox)

Experimental

a 7-day quadruple regimen with dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with dexlansoprazole MR 60 mg once daily and amoxicillin 1 g twice daily

干预措施: (dexlan+amox+clar+metr)+(dexlan+amox) (Drug)

dexlan+clarith+amox+metro

Active Comparator

dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily for 14 days

干预措施: dexlan+clarith+amox+metro (Drug)

结局指标

主要结局

Number of Participants in Which H. Pylori Was Eradicated

时间窗: sixth week after the end of anti- H. pylori therapy

To assess eradication efficacy,repeated endoscopy with rapid urease test, histological examination and culture or Urea breath test.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ping-I (William) Hsu, M.D.

Professor

Kaohsiung Veterans General Hospital.

研究点 (1)

Loading locations...

相似试验